JonesResearch analyst Soumit Roy downgraded Anavex (AVXL) to Hold from Buy without a price target Anavex’s valuation is entirely dependent on the decision from the European Medicines Agency regarding the approval of blarcamesine in Alzheimer’s disease, the analyst tells investors in a research note. The firm sees the decision coming in Q1 of 2026. It cites Anavex’s current valuation and potential downside on the news for the downgrade.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex announces development of oral tablet formulation for ANAVEX3-71 program
- Anavex announces Phase 2 study of ANAVEX3-71 met its primary endpoint
- Anavex announces publication on oral blarcamesine Phase IIb/III trial
- Promising Clinical Data and Market Potential Drive Buy Rating for Anavex Life Sciences
- Anavex announces latest findings for blarcamesine